Global life sciences industry calls for action on vaccine access

19 May 2021
novavax_vaccine_large

Trade bodies representing the global life sciences industry have come together to urge coordinated steps to improve access to coronavirus vaccines.

In a statement, the groups said: “Immediate action must focus on stepping up responsible dose sharing and maximizing production without compromising quality or safety.”

The call to action has been issued by leading European trade group The European Federation of Pharmaceutical Industries and Associations (EFPIA) and the USA’s Pharmaceutical Research and Manufacturers of America (PhRMA), as well as several other national and regional bodies.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology